Exclusive analysis of biotech, pharma, and the life sciences
Account
More
Follow Us
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
By Adam Feuerstein Sept. 29, 2021
An experimental CRISPR-based treatment from Editas Medicine led to meaningful improvements in the functional vision of a single patient born with a rare, genetic disease that leads to blindness — a preliminary study outcome that Editas called encouraging but that also raises some concerns its gene-editing approach is not potent enough.
The first clinical data from Editas’ treatment, called EDIT-101, were presented Wednesday at a research meeting. One patient out of four treated with a middle dose of EDIT-101 showed meaningful improvements across several different measures of functional vision. A low dose of the treatment tested in two patients was ineffective.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
Senior Writer, Biotech
Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast.
biotechnology
CRISPR
STAT+
This name will appear with your comment
There was an error saving your display name. Please check and try again.
By Adam Feuerstein
By Adam Feuerstein
advertisement
By Erin Brodwin
By Ed Silverman
By
Reporting from the frontiers of health and medicine